Boehringer Ingelheim GmbH Market Share Analysis

Boehringer Ingelheim GmbH Market Share Analysis

Summary

GlobalData’s new report, “Boehringer Ingelheim GmbH Market Share Analysis” provides in-depth information on Boehringer Ingelheim GmbH’s market position in the metered dose inhaler devices market. The report also provides data and information on the overall competitive landscape within the metered dose inhaler devices market. The report is supplemented with global corporate-level profile with information on the company’s business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Global company shares (in Revenues) information for the metered dose inhaler devices market.
• Boehringer Ingelheim GmbH’s company shares (in Revenues) information for all the key countries the company has presence in – India, Japan, China, Australia, United Kingdom, France, Germany, Spain, Italy, United States, Canada and Brazil.
• Boehringer Ingelheim GmbH’s company shares (in Revenues) information for the metered dose inhaler devices market.
• All the key data-points are for 2010 and cover all the key regions – North America, Middle East and Africa, Europe, Asia-Pacific and South and Central America.
• Global corporate-level profile with information on the company’s business segments, major products and services, competitors, and locations and subsidiaries.
• The company profile is also supplemented with a SWOT Analysis with in-depth information and analysis of the company’s value proposition and the business climate it operates in.
• Comprehensive coverage of the latest financial deals involving the company and its subsidiaries, if any.

Reasons to buy

• Develop sales and marketing strategies by identifying who-stands-where in the markets, Boehringer Ingelheim GmbH’s operates in.
• Plan your competition strategies by identifying the company’s shares in the markets and geographic regions it operates in.
• Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are involved in.
• Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in the report.
• Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not limited to Boehringer Ingelheim GmbH’s market positions.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 What Is This Report About?

3 DEFINITIONS OF MARKETS/CATEGORIES COVERED

3.1 Metered Dose Inhaler Devices

4 COMPANY SNAPSHOT

4.1 Key Information
4.2 Company Overview
4.3 SWOT Snapshot

5 BUSINESS DESCRIPTION

5.1 Business Overview
5.2 Animal Health
  5.2.1 Overview
  5.2.2 Financials
  5.2.3 Market View
5.3 Human Pharmaceuticals
  5.3.1 Overview
  5.3.2 Financials
  5.3.3 Market View
5.4 Major Products and Services
  5.4.1 Overview

6 HISTORY

7 BUSINESS STRATEGY

7.1 Mission Statement

8 SWOT ANALYSIS

8.1 Overview
8.2 Boehringer Ingelheim GmbH Strengths
  8.2.1 Delivering Value through Innovation
  8.2.2 Global Presence
  8.2.3 Contract Manufacturing
8.3 Boehringer Ingelheim GmbH Weaknesses
  8.3.1 Patent Expiry
  8.3.2 Voluntary Product Recalls
8.4 Boehringer Ingelheim GmbH Opportunities
  8.4.1 Inorganic Growth Strategy
  8.4.2 Market Growth in Emerging Economies
  8.4.3 Growing CRO Industry
  8.4.4 Market Potential
8.5 Boehringer Ingelheim GmbH Threats
  8.5.1 Tightening of FDA’s Regulatory Oversight
  8.5.2 Cost Containment Pressures
  8.5.3 Uncertain R&D Outcomes

9 COMPETITORS

10 COMPETITIVE LANDSCAPE

10.1 Metered Dose Inhaler Devices Global, Market Share (%), 2010

11 BOEHRINGER INGELHEIM GMBH MEDICAL EQUIPMENT MARKET SHARE ANALYSIS

11.1 Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Global, Market Share (2010)
11.2 Boehringer Ingelheim GmbH, Asia-Pacific, Market Share (2010)
11.3 Boehringer Ingelheim GmbH, Europe, Market Share (2010)
11.4 Boehringer Ingelheim GmbH, Middle East and Africa, Market Share (2010)
11.5 Boehringer Ingelheim GmbH, North America, Market Share (2010)
11.6 Boehringer Ingelheim GmbH, South and Central America, Market Share (2010)

12 KEY EMPLOYEES

13 KEY EMPLOYEE BIOGRAPHIES

14 COMPANY STATEMENT

15 LOCATIONS AND SUBSIDIARIES

15.1 Head Office
15.2 Other Locations & Subsidiaries

16 FINANCIAL DEALS LANDSCAPE

16.1 Boehringer Ingelheim GmbH, Deals Volume Summary, 2006 to YTD 2011

17 BOEHRINGER INGELHEIM GMBH DETAILED DEAL SUMMARY

17.1 Partnerships
  17.1.1 Vectura Signs An Agreement With Boehringer Ingelheim
17.2 Equity Offering
    17.2.1.1 Vectura Group Completes Private Placement Of $7.22 Million
  17.2.2 Vectura Group Completes Private Placement Of $12.83 Million

18 RECENT DEVELOPMENTS

18.1 Strategy and Business Planning
  18.1.1 Feb 15, 2011: Pfenex And Boehringer Ingelheim Sign Non-Exclusive Strategic Agreement For Use Of Pfenex Expression Technology
  18.1.2 Nov 27, 2009: Boehringer Ingelheim, Vectura Terminate Collaboration
  18.1.3 Nov 09, 2009: Evotec Extends Research Collaboration With Boehringer Ingelheim
  18.1.4 Oct 22, 2009: Evotec Obtains E2.5m Milestone Payment From Boehringer Ingelheim
  18.1.5 Jun 15, 2009: Boehringer Ingelheim, Vitae Collaborate For Development Of Beta-Secretase Inhibitors
  18.1.6 May 29, 2009: Boehringer Ingelheim, DxS Sign Collaboration Agreement
  18.1.7 Jun 17, 2008: Boehringer Ingelheim To Acquire Actimis Pharmaceuticals
  18.1.8 Apr 19, 2006: Vectura Enters Agreement With Boehringer Ingelheim
18.2 Financial Announcements
  18.2.1 Jul 28, 2009: Boehringer Ingelheim Posts First Half Financial Results
  18.2.2 Aug 07, 2008: Boehringer Reports 1H 2008 Results
  18.2.3 Jul 26, 2007: Boehringer Declares H1 2007 Results
18.3 Research And Development
  18.3.1 Nov 22, 2010: f-star And Boehringer Ingelheim Partner To Develop New Therapeutic Antibodies
  18.3.2 Oct 26, 2010: Boehringer Ingelheim Partners With MacroGenics To Discover, Develop And Commercialize DART-Based Antibody Therapeutics
  18.3.3 Aug 26, 2010: Boehringer Ingelheim Opens Center of Competence In Shanghai
18.4 Corporate Communications
  18.4.1 Jun 26, 2008: Boehringer Ingelheim Announces Board Changes
18.5 Government and Public Interest
  18.5.1 Oct 23, 2009: EMEA Issues Positive Opinion For Micardis
  18.5.2 Oct 14, 2009: Boehringer Ingelheim Receives Marketing Authorisation From European Commission For Mirapexin/Sifrol
  18.5.3 Oct 07, 2009: Astellas, Boehringer Ingelheim Reach Settlement With Impax

19 APPENDIX

19.1 Research Methodology
19.2 Secondary Research
19.3 Primary Research
19.4 Models
19.5 Forecasts
19.6 Expert Panels
19.7 GlobalData Consulting
19.8 Currency Conversion
19.9 Contact Us
19.10 Disclaimer

LIST OF TABLES

Table 1: Boehringer Ingelheim GmbH, Key Facts, 2010
Table 2: Boehringer Ingelheim GmbH, SWOT Analysis, 2010
Table 3: Metered Dose Inhaler Devices, Global, Company Share by Revenue ($m), 2010
Table 4: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Global, Revenue ($m) and Market Share (%), 2010
Table 5: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Asia-Pacific, Revenue ($m) and Market Share (%), 2010
Table 6: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Europe, Revenue ($m) and Market Share (%), 2010
Table 7: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Middle East and Africa, Revenue ($m) and Market Share (%), 2010
Table 8: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, North America, Revenue ($m) and Market Share (%), 2010
Table 9: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, South and Central America, Revenue ($m) and Market Share (%), 2010
Table 10: Boehringer Ingelheim GmbH, Key Employees
Table 11: Boehringer Ingelheim GmbH, Other Locations
Table 12: Boehringer Ingelheim GmbH, Subsidiaries
Table 13: Boehringer Ingelheim GmbH, Deals Volume Summary, 2006 to YTD 2011
Table 14: Boehringer Ingelheim GmbH, Deals Summary, 2006 to YTD 2011
Table 15: Vectura Signs An Agreement With Boehringer Ingelheim
Table 16: Vectura Group Completes Private Placement Of $7.22 Million
Table 17: Vectura Group Completes Private Placement Of $12.83 Million
Table 18: USD to Local Currency, Average Exchange, Rate 2010

LIST OF FIGURES

Figure 1: Metered Dose Inhaler Devices, Global, Market Share (%), 2010
Figure 2: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Global, Market Share (%), 2010
Figure 3: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Asia-Pacific, Market Share (%), 2010
Figure 4: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, Europe, Market Share (%), 2010
Figure 5: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, North America, Market Share (%), 2010
Figure 6: Boehringer Ingelheim GmbH, Metered Dose Inhaler Devices, South and Central America, Market Share (%), 2010
Figure 7: Boehringer Ingelheim GmbH, Deals Volume Summary, 2006 to YTD 2011

COMPANIES MENTIONED

3M HEALTH CARE
AstraZeneca International plc
Bayer HealthCare AG
Bristol-Myers Squibb Company
Consort Medical plc
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co., Inc
Novartis AG
Pfizer Inc.
Sunovion Skip to top